Results 101 to 110 of about 16,072 (215)

Leishmaniavirus-dependent metastatic leishmaniasis is prevented by blocking IL-17A [PDF]

, 2016
Cutaneous leishmaniasis has various outcomes, ranging from self-healing reddened papules to extensive open ulcerations that metastasise to secondary sites and are often resistant to standard therapies. In the case of L.
Beverly, Stephen M, Bourreau, Ellane, Castiglioni, Patrik, Coupple, Pierre, Eren, Remzi Onur, Fasel, Nicholas, Hartley, Mary-Anne, Hickerson, Suzanne M, Launois, Pascal, Prevel, Florence, Ronet, Catherine, Rossi, Matteo   +11 more
core   +4 more sources

Metabolism of formycin B by Leishmania amastigotes in vitro. Comparative metabolism in infected and uninfected human macrophages. [PDF]

, 1983
Formycin B is metabolized by cutaneous Leishmania amastigotes within cultured human macrophages to give formycin B 5'-monophosphate and formycin A 5'-mono-, di-, and triphosphates. Formycin A is also incorporated into RNA.
Berman, JD, Rainey, P, Santi, DV
core  

Topical formulations of miltefosine for cutaneous leishmaniasis in a BALB/c mouse model. [PDF]

, 2016
UNLABELLED: Cutaneous leishmaniasis (CL) is caused by several species of the protozoan parasite Leishmania and affects approximately 10 million people worldwide.
Croft, Simon L, Murdan, Sudaxshina, Van Bocxlaer, Katrien, Yardley, Vanessa   +3 more
core   +2 more sources

Altered miRNA expression in the lesions of cutaneous leishmaniasis caused by L. major and L. tropica with insights into apoptosis regulation

Scientific Reports
Leishmaniasis is a vector-borne infectious disease that affects many subtropical countries. Leishmania (L.) major and L. tropica are among the old-world causative agents and cause cutaneous leishmaniasis (CL).
Taha Masoudsinaki, Shima Hadifar, Hamzeh Sarvnaz, Mohammad Farahmand, Nasrin Masoudzadeh, Vahid Mashayekhi Goyonlo, Mohammadali Kerachian, Reza Erfanian Salim, Mourad Barhoumi, Seyed Latif Mousavi Gargari, Hossein Heydari, Sima Rafati   +11 more
doaj   +1 more source

Evaluation of farnesol orally and topically against experimental cutaneous leishmaniasis: In -vivo analysis. [PDF]

PLoS One, 2023
Sharma H, Sehgal R, Jhacak S, Deshmukh K, Nada R.   +4 more
europepmc   +1 more source

HisAK70: Progress towards a vaccine against different forms of leishmaniosis [PDF]

, 2015
Background: Leishmania major and Leishmania infantum are among the main species that are responsible for cutaneous leishmaniosis (CL) and visceral leishmaniosis (VL), respectively.
A Ghosh, A Liang, A Nieto, A Romano, Abel Martínez-Rodrigo, AH Ding, Alicia Mas, C Maia, C Maia, C Ravel, CD Mathers, CE Stebeck, CR Engwerda, D Nico, D Raab, D Sacks, DC Matos, DI Lacerda, DL Sacks, DL Sacks, DM Claborn, E Dumonteil, E McFarlane, E Stebut Von, F Dantas-Torres, F Dantas-Torres, FH Zanin, G Dominguez-Bernal, G Dominguez-Bernal, G Kwakye-Nuako, Gustavo Domínguez-Bernal, HW Murray, HW Murray, HY Kang, J Alexander, J Alvar, J Carrion, J Carrion, J Li, Javier Carrión, JE Galan, José A. Orden, José A. Ruiz-Santa-Quiteria, JW Moore, K Seifert, KC Carter, L Kedzierski, L Ramirez, Lara Ordóñez-Gutiérrez, M Agallou, M Agallou, M Agallou, M Antoniou, M Rath, MB Lutz, ME Bottazzi, O Riede, P Desjeux, P Ready, P Scott, PA Buffet, PD Ready, PD Ready, Pilar Horcajo, PJ Hotez, R Basu, R Guha, R Kumar, R Sachdeva, Ricardo De La Fuente, S Bhaumik, S Iborra, S Mukhopadhyay, S Rafati, VV Garrido, WW Zhang   +75 more
core   +1 more source

Immunity and immunosuppression in experimental visceral leishmaniasis

Brazilian Journal of Medical and Biological Research, 2004
Leishmaniasis is a disease caused by protozoa of the genus Leishmania, and visceral leishmaniasis is a form in which the inner organs are affected. Since knowledge about immunity in experimental visceral leishmaniasis is poor, we present here a review on
Goto H., Lindoso J.A.L.
doaj  

Cytokine profile and pathology in human leishmaniasis

Brazilian Journal of Medical and Biological Research, 1998
The clinical spectrum of leishmaniasis and control of the infection are influenced by the parasite-host relationship. The role of cellular immune responses of the Th1 type in the protection against disease in experimental and human leishmaniasis is well ...
A. Ribeiro-de-Jesus, R.P. Almeida, H. Lessa, O. Bacellar, E.M. Carvalho   +4 more
doaj   +1 more source

Topical Treatment for Cutaneous Leishmaniasis: Dermato-Pharmacokinetic Lead Optimization of Benzoxaboroles. [PDF]

, 2018
Cutaneous leishmaniasis (CL) is caused by several species of the protozoan parasite Leishmania, affecting an estimated 10 million people worldwide. Previously reported strategies for the development of topical CL treatments have focused primarily on drug
Croft, Simon L, Gaukel, Eric, Hauser, Deirdre, Jacobs, Robert T, Merchant, Tejal, Park, Seong Hee, Plattner, Jacob J, Randolph, Ryan, Schock, Sara, Van Bocxlaer, Katrien, Wring, Stephen A, Yardley, Vanessa   +11 more
core   +1 more source

First-line therapy for human cutaneous leishmaniasis in Peru using the TLR7 agonist imiquimod in combination with pentavalent antimony.

PLoS Neglected Tropical Diseases, 2009
BackgroundCurrent therapies for cutaneous leishmaniasis are limited by poor efficacy, long-term course of treatment, and the development of resistance.
Cesar Miranda-Verastegui, Gianfranco Tulliano, Theresa W Gyorkos, Wessmark Calderon, Elham Rahme, Brian Ward, Maria Cruz, Alejandro Llanos-Cuentas, Greg Matlashewski   +8 more
doaj   +1 more source